Nuvation Bio vs Rigel Pharmaceuticals
NUVB and RIGL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NUVB and RIGL compare
Nuvation Bio is the larger company, worth 1.7 times as much as Rigel Pharmaceuticals ($1.4B against $831M).
Nuvation Bio grew revenue faster over the last twelve months (654% versus 2.2% for Rigel Pharmaceuticals).
Rigel Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 107% compared with −67.4% at Nuvation Bio.
Rigel Pharmaceuticals scores higher on the StockData Score (11 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NUVB | RIGL |
|---|---|---|
| Size and price | ||
| Market cap | $1.4B | $831M |
| Share price | $3.99 | $44.46 |
| Change, 1 year | −19.1% | 11.3% |
| Change, 5 years | −55.9% | 45.8% |
| Beta (5Y) | 1.45 | 1.08 |
| Employees | 298 | 174 |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 4 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 2.9× |
| P/S | 6.9× | 2.9× (better) |
| P/B | 6.1× | 1.9× (better) |
| EV/EBITDA | – | 9.2× |
| Fair value | $1.94 | – |
| Margin of safety | −105% | – |
| Growth | ||
| Revenue growth (TTM) | 654% (better) | 2.2% |
| Revenue growth, 5Y average | – | 22.1% |
| Net income growth (TTM) | – | 171% |
| EPS growth (TTM) | – | 147% |
| Profitability | ||
| Gross margin | – | 89.6% |
| Operating margin | −61.2% | 26.3% (better) |
| Net margin | −67.4% | 107% (better) |
| Return on equity | −49.1% | 109% (better) |
| Return on invested capital | – | 46.4% |
| Financial health | ||
| Debt / equity | 0.03 | – |
| Interest coverage | −5.9× | 18.2× (better) |
| Current ratio | 7.45 (better) | 2.39 |
| Altman Z-score | 0.06 | 4.98 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 87.7% |
| Held by insiders | 24.6% | 3.3% |
| Insider net buying, 12 months | −$4.5M | −$306K (better) |
| Superinvestors holding | 2 | – |
| Short interest, % of float | 23.4% | 14.0% |
Go deeper
- NUVB stock overview
- NUVB income statement
- NUVB valuation and score
- RIGL stock overview
- RIGL income statement
- RIGL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.